Just released today at the UK Cystic Fibrosis Trust Conference. Data looks good, as the half life +34% compared to Kalydeco, and other PK measures by far outperformed. Data below is a single dose of CTP-656 150 mg, compared to a single dose of Kalydeco 150mg.
C 12hr +320%
C 24hr +420%
AUC 24hr +280%
C max +100%
T 1/2 +34%
Of note, at steady state, Kalydeco exposure is predominately to less active metabolites compared to CTP-656. This could potentially have CTP-656 being more efficacious than Kalydeco.
Bottom Line: This was a good 15 minute presentation that displayed CTP-656 from a comparison, to Vertex drug Kalydeco. The company reported that "CTP-656 was well-tolerated across all dose groups (75, 150, and 300 mg). There were no serious adverse events reported in subjects who received CTP-656." Vertex at present, holds a monopoly drug for CF patients, $300,000 per year therapy. I think in two to three years, there could potentially be a competing therapy of drugs, lower priced, with a better drug to drug interaction profile, with potential for single daily dosing. Thank you for reading.
C 12hr +320%
C 24hr +420%
AUC 24hr +280%
C max +100%
T 1/2 +34%
Of note, at steady state, Kalydeco exposure is predominately to less active metabolites compared to CTP-656. This could potentially have CTP-656 being more efficacious than Kalydeco.
Bottom Line: This was a good 15 minute presentation that displayed CTP-656 from a comparison, to Vertex drug Kalydeco. The company reported that "CTP-656 was well-tolerated across all dose groups (75, 150, and 300 mg). There were no serious adverse events reported in subjects who received CTP-656." Vertex at present, holds a monopoly drug for CF patients, $300,000 per year therapy. I think in two to three years, there could potentially be a competing therapy of drugs, lower priced, with a better drug to drug interaction profile, with potential for single daily dosing. Thank you for reading.
It was very useful for me. Keep sharing such ideas in the future as well. This was actually what I was looking for, and I am glad to came here! Thanks for sharing the such information with us.
ReplyDeleteGreat, Keep it up! I really admire your writing skills.
ReplyDelete